These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8501502)

  • 1. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
    Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling toxicity and response in carboplatin-based combination chemotherapy.
    Egorin MJ; Reyno LM; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):7-19. PubMed ID: 7992070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
    Jodrell DI; Egorin MJ; Canetta RM; Langenberg P; Goldbloom EP; Burroughs JN; Goodlow JL; Tan S; Wiltshaw E
    J Clin Oncol; 1992 Apr; 10(4):520-8. PubMed ID: 1548516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients.
    Sørensen BT; Strömgren A; Jakobsen P; Jakobsen A
    Cancer Chemother Pharmacol; 1991; 28(5):397-401. PubMed ID: 1914085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin.
    Fujiwara K; Yamauchi H; Suzuki S; Ishikawa H; Tanaka Y; Fujiwara M; Kohno I
    Cancer Chemother Pharmacol; 2001; 47(1):22-6. PubMed ID: 11221957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
    Bookman MA; McGuire WP; Kilpatrick D; Keenan E; Hogan WM; Johnson SW; O'Dwyer P; Rowinsky E; Gallion HH; Ozols RF
    J Clin Oncol; 1996 Jun; 14(6):1895-902. PubMed ID: 8656258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
    Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
    Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
    J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
    van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
    Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.